louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05230693: SPARC Smartphone Application for the Management of Sarcoidosis-Associated Fatigue
Official title: The SPARC App: A Smartphone Application for the Management of Sarcoidosis-Associated Fatigue
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sarcoidosis
Fatigue
Lead sponsor: Medical University of South Carolina
Sponsor class: OTHER
Collaborators: name: National Institute for Biomedical Imaging and Bioengineering (NIBIB)
First posted: 2022-02-09
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Fatigue is a pervasive and disabling symptom in sarcoidosis with limited treatment options. There is a significant association between heightened stress and sarcoidosis-associated fatigue. The proposed project will evaluate the usability/feasibility of a smartphone-based stress management application for the self-management of sarcoidosis-associated stress and fatigue.


Eligibility criteria: Inclusion Criteria:

* Sarcoidosis diagnosis based on established criteria
* ≥18 years old
* able to speak, hear, and understand English
* elevated SAF (FAS score ≥22)
* owns smartphone with current data plan
* willingness and ability to use app to engage in Breathing Awareness Meditation (BAM)

Exclusion Criteria:

* history of psychotic disorder, bipolar disorder, eating disorder, narcolepsy, cancer diagnosis or treatment in past 12 months
* positive screening for potential major depression (Patient Health Questionnaire depression scale \[PHQ-8; α = .86\] score ≥10)
* untreated sleep apnea (based on home sleep study testing)
* sarcoidosis exacerbation in past 3 months requiring increase in sarcoidosis medications
* \>2 hr travel distance to medical center (to reduce likelihood of no-show for focus groups)
* active substance abuse or binge drinking (\>21 drinks/week )

Primary outcomes:
measure: Proportion of Participants Recruited
timeFrame: 6 months
measure: Number of Participants Who Complete the Study
timeFrame: 6 months
measure: Number of Participants Who Maintain Adherence to at Least Daily Daily Breathing Awareness Meditation Sessions
timeFrame: 3 months
measure: Treatment Satisfaction
timeFrame: Month 3
Secondary outcomes:
measure: Change in Sarcoidosis Associated Fatigue From Baseline to Month 6
timeFrame: Week 0 and Week 24
measure: Changes in Self-Efficacy From Baseline to Month 3
timeFrame: Week 0 and Week 12
measure: Changes in Stress From Baseline to Month 6
timeFrame: Week 0 and Week 24
measure: Changes in Autonomous Motivation
timeFrame: Week 0 and Week 24
measure: Changes in Quality of Life
timeFrame: Week 0 and Week 24
Other outcomes:
Locations:
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
Study officials:
References:
Clinical trial NCT01311193: Circadian Sleep-wake Cycles and Light Therapy in Borderline Personality Disorder
Official title: Circadian Sleep-wake Cycles, Well-being and Light Therapy in Borderline Personality Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Borderline Personality Disorder
Sleep Disturbances
Depression
Keywords: Circadian rhythms
Sleep-wake cycles
Melatonin
Borderline Personality Disorder
Light therapy
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
Collaborators: name: Velux Fonden
name: Lumie UK
First posted: 2011-03-09
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT

Brief summary: Individuals with borderline personality disorder (BPD) frequently suffer from emotional instability, daytime fatigue and sleep disturbances. The investigators examined circadian rhythms, sleep and well-being in women with BPD under their habitual life conditions with and without light treatment.

Treated women diagnosed with BPD were investigated during 3 weeks without and 3 weeks with morning LT. Rest-activity cycles were continuously measured using wrist actigraphy, together with proximal skin temperature. Saliva samples were collected weekly to determine the diurnal melatonin rhythm. A range of self-ratings and questionnaires were used to assess depression and clinical state throughout the 6-week protocol. Ten matched healthy women followed the same 6-week protocol without light treatment.


Eligibility criteria: Inclusion Criteria:

* Borderline Personality Disorder (DSM IV-criteria)
* German-speaking
* normal ocular function

Exclusion Criteria:

* lack of compliance

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Centre for Chronobiology, Psychiatric Hospital, University of Basel
state: BS
Study officials:
affiliation: Centre for Chronobiology, Psychiatric Hospital, University of Basel
name: Christian Cajochen, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01082393: Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)
Official title: Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Vitiligo
Keywords: vitiligo
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2010-03-08
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: We will investigate the process of vitiligo induction and the influence of different commonly used cream treatments on this process. Studies comparing different treatments for vitiligo in the induction stage of the disease are still missing. The study hypothesis = cream treatment can stop actively spreading vitiligo lesions during the early induction stage of the disease.


Eligibility criteria: Inclusion Criteria:

* Male and female,
* Age 18-70 years,
* Extensive vitiligo (\> 50% body surface area),
* Patients asking for depigmenting therapy,
* Not pregnant.

Exclusion Criteria:

* Children,
* Non extensive vitiligo (\< 50% boy surface area),
* Patients not asking for depigmenting therapies,
* Pregnant.

Primary outcomes:
measure: percentage of skin pigmentation in the treated area
timeFrame: after 1 day, 10 days, 30 days and 60 days
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Nanny Van Geel, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01773993: Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)
Official title: SPECIAL INVESTIGATION OF PREGABALIN FOR FIBROMYALGIA
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain Associated With Fibromyalgia
Keywords: Lyrica
pregabalin
Good post marketing practice
Post Marketing Surveillance
Regulatory Post Marketing Commitment Plan
Fibromyalgia
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2013-01-23
Enrollment: 534
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Primary care clinic and hospital for Fibromyalgia

Brief summary: To collect the efficacy and safety information of Pregabalin on Fibromyalgia patients related to their appropriate use in daily practice.

Detailed description: All the patients whom an investigator prescribes the first pregabalin should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Fibromyalgia
* Pregabalin naive patient

Exclusion Criteria:

* Clinical diagnosis of neuropathic pain

Primary outcomes:
measure: Percentage of Participants With Adverse Drug Reaction
timeFrame: From Week 1 to 52 weeks at maximum
Secondary outcomes:
measure: Percentage of Participants With Serious Adverse Drug Reaction
timeFrame: From Week 1 to52 weeks
measure: Percentage of Participants With Adverse Drug Reaction Unexpected From Japanese Package Insert
timeFrame: From Week 1 to 52 weeks
measure: Number of Participants With Adverse Drug Reactions Related to Peripheral Edema or Other Edema-related Events
timeFrame: From Week 1 to 52 weeks
measure: Number of Participants With Adverse Drug Reactions Related to Dizziness, Somnolence, Loss of Consciousness, Syncope, and Potential for Accidental Injury
timeFrame: From Week 1 to 52 weeks
measure: Number of Participants With Adverse Drug Reactions Related to Vision-related Events
timeFrame: From Week 1 to 52 weeks
measure: Change From Baseline in Pain Score at Week 52
timeFrame: Baseline and at Week 52
measure: Change From Baseline in Quality of Sleep Score at Week 52
timeFrame: Baseline and at Week 52
measure: Patient's Impression (PGIC) at Week 52
timeFrame: At Week 52
measure: Physician's Impression (CGIC) at Week 52
timeFrame: At Week 52
measure: Change From Baseline in Patient Health Questionnaire (PHQ-9) Score at Week 52
timeFrame: Baseline and at Week 52
measure: Change From Baseline in Health Status of EuroQol 5 Dimension (EQ-5D) at 52 Weeks
timeFrame: Baseline and at Week 52
measure: Change From Baseline in Fibromyalgia Activity Score (FAS-31) at 52 Weeks
timeFrame: At Week 52
measure: Change From Baseline in the Japanese Version of the Revised Fibromyalgia Impact Questionnaire (JFIQR) at 52 Weeks
timeFrame: At Week 52
Other outcomes:
Locations:
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT05468593: Patient Outcomes After Hepatic Artery Infusion Pump Placement
Official title: Patient Reported Outcomes After Hepatic Artery Infusion Pump Placement
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colorectal Liver Metastases
Colorectal Cancer
Keywords: Hepatic Artery Infusion
Pump
Hepatic Artery Infusion Chemotherapy
Unresectable Colorectal Liver Metastases
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2022-07-21
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with colorectal liver metastases (CRLM) being offered Hepatic Artery Infusion Pump placement and subsequent Hepatic Artery Infusion Chemotherapy at Mayo Clinic Rochester will be evaluated to participate in this study.

Brief summary: The purpose of this study is to evaluate the surgical outcomes and the quality of life (QOL) in patients undergoing hepatic artery infusion pump placement for colorectal liver metastases (CRLM).


Eligibility criteria: Inclusion Criteria:

* Patients who receive a Hepatic Artery Infusion Pump at Mayo Clinic Rochester for liver metastases from colorectal cancer.
* Written consent.

Exclusion Criteria:

* Absence of written consent.
* Systemic disease.
* Pregnancy.

Primary outcomes:
measure: Quality of Life
timeFrame: Baseline prior to surgery.
measure: Quality of Life
timeFrame: Postoperative day 2.
measure: Quality of Life
timeFrame: Postoperative day 7.
measure: Quality of Life
timeFrame: Postoperative day 14.
measure: Quality of Life
timeFrame: Postoperative day 30.
measure: Quality of Life
timeFrame: Postoperative day 60.
measure: Quality of Life
timeFrame: Postoperative day 90.
measure: Quality of Life
timeFrame: Postoperative day 120.
measure: Quality of Life
timeFrame: Postoperative day 150.
measure: Quality of Life
timeFrame: Postoperative day 180.
Secondary outcomes:
measure: Time to start chemotherapy
timeFrame: 1 month postoperatively
measure: Surgical outcomes
timeFrame: 1 month postoperatively
measure: Surgical outcomes
timeFrame: 6 month postoperatively
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Cornelius Thiels, DO, MBA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02722993: Efficacy of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Antibiotic-associated Diarrhea
Lead sponsor: Probi AB
Sponsor class: INDUSTRY
First posted: 2016-03-30
Enrollment: 117
Sex: ALL
Minimum age (years): 1
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To assess the effect of a probiotic product, when co-administered with antibiotics, on gastrointestinal symptoms following antibiotic treatment in children.


Eligibility criteria: Inclusion Criteria:

* Children at the age of 1-11 years that have been prescribed antibiotic treatment.
* Problems with loose stools during earlier antibiotic treatments.
* Children whose parents or legal caregivers have signed the informed consent to participate in the study.

Exclusion Criteria:

* Chronic intestinal disease, immunodeficiency or immunosuppressive treatment.
* Chronic or acute diarrheal disease.
* Use of laxatives the week before inclusion in the study.
* Antibiotic treatment for the last four weeks before inclusion in the study.
* Intake of probiotic products for the last two weeks before inclusion in the study.
* Known hypersensitivity to any of the ingredients in the probiotic product or the placebo (potato starch ± bacterial culture that may contain traces of soy).
* Patient requiring hospitalisation.

Primary outcomes:
measure: Number of loose/watery stools
timeFrame: 19-26 days
Secondary outcomes:
Other outcomes:
Locations:
city: Warszawa
country: Poland
Study officials:
affiliation: Children's Memorial Health Institute, Warzaw, Poland
name: Piotr Socha, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05880693: Comparisons Between Dexmedetomidine and Magnesium Sulfate in Controlled Hypotension During Rhinoplasty Surgeries
Official title: Dexmedetomidine Versus Magnesium Sulfate in Controlled Hypotension During Rhinoplasty Surgeries
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hypotension
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
Collaborators: name: Al-Azhar University
First posted: 2023-05-30
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 56 patients got enrolled and then divided into two groups. Group 1 received dexmedetomidine (n=28), while the group 2 received magnesium sulfate (n=28). MAP, as well as heart rate, were recorded. Surgeon satisfaction was approximated for the surgical field quality.
Primary purpose: PREVENTION

Brief summary: General anesthesia organizes the best option for controlled blood pressure during rhinoplasty surgery. The primary agent applied in controlling hypotension should have particular unique characteristics. The dexmedetomidine central and peripheral sympatholytic performance is usually indicated by low blood pressure and low heart rate. magnesium sulfate is among the best agents used.

Detailed description: This is a prospective comparative randomized study. 56 patients got enrolled and then divided into two groups. Group 1 received dexmedetomidine (n=28), while the group 2 received magnesium sulfate (n=28). MAP, as well as heart rate, were recorded. Surgeon satisfaction was approximated for the surgical field quality. The amount of blood loss during the entire process was measured. The score of pain was evaluated using the NRS rating scale. Sedation score through Ramsey sedation score. The time required for the first requirement of analgesia was also recorded as well as intraoperative and postoperative problems.

Eligibility criteria: Inclusion Criteria:

1. 18-60 years old
2. ASA (American Society of Anesthesiologists) grading I and II
3. patients undergo rhinoplasty surgery under general anesthesia

Exclusion Criteria:

1. The pregnant ladies
2. patients suffering from hypertension ischemic heart diseases renal insufficiency, neuromuscular diseases, hepatic impairment
3. cerebrovascular inadequacy and diabetic neuropathy, coagulopathies,
4. patients taking antiplatelets
5. Refused study,
6. patients of age \< 18 or \> 60 were unauthorized from the study.

Primary outcomes:
measure: The primary outcome was to determine the bleeding score
timeFrame: 24 hours postoperative period
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Mohamed gawad Abdel aboelsuod
Study officials:
affiliation: AZHAR
name: Mohamed GA aboelsuod
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01757093: Evaluation of Oxygen Consumption and Energy Expenditure During Spontaneous Breathing Trial.
Official title: Evaluation of Oxygen Consumption and Energy Expenditure During Spontaneous Breathing Trial - A Randomized Crossover Controled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Respiratory Failure
Keywords: INDIRECT CALORIMETRY
MECHANICAL VENTILATION
WEANING VENTILATOR
AUTOMATIC TUBE COMPENSATION
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
First posted: 2012-12-28
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to compare the oxygen consumption and energy expenditure during the spontaneous breathing trial.

Detailed description: Patients is going to submit to the 2 spontaneous breathing trial ( Automatic tube compensation plus continuous positive airway pressure and continuous positive airway pressure without automatic tube compensation. The oxygen consumption and energy expenditure is going to measure during the spontaneous breathing trial by indirect calorimetry.

Eligibility criteria: Inclusion Criteria:

* IMPROVEMENT OR RESOLUTION OF THE UNDERLYING CAUSE OF DISEASE
* INTUBATED PATIENTS\>24h
* PaO2 GREATER THAN 60 mmHg WITH FiO2 LESS THAN 40%
* PEEP=5 cmH2O

Exclusion Criteria:

* CARDIOVASCULAR INSTABILITY
* FEBRILE OR HYPOTHERMIA
* CHEST DRAINAGE
* RESPIRATORY RATE/TIDAL VOLUME RATIO GREATER THAN 105
* PREGNANCY
* FAIL IN THE SPONTANEOUS BREATHING TRIAL
* LEAKS IN THE CIRCUIT
* AGITATION
* NOT ACCEPT PARTICIPATE IN THE STUDY

Primary outcomes:
measure: Measurement of oxygen consumption through indirect calorimetry.
timeFrame: The measurement is during the spontaneous breathing trial, 30 minutes.
Secondary outcomes:
measure: Measurement of energy expenditure through indirect calorimetry
timeFrame: The measurement is during the spontaneous breathing trial, 30 minutes.
Other outcomes:
Locations:
city: Ribeirão Preto
country: Brazil
facility: Hospital Das Clínicas Da Faculdade de Medicina de Ribeirão Preto -Universidade de São Paulo
state: São Paulo
Study officials:
affiliation: University of Sao Paulo
name: Alessandra Fa Lago, physiotherap
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01009671: Study to Evaluate the Digestive Tolerability of ART44 Versus ART®50 in Patients With Osteoarthritis of the Knee
Official title: Randomised, Comparative, Double-blind, Parallel-group Study to Evaluate the Digestive Tolerability of ART44 Versus ART®50 in Patients With Osteoarthritis of the Knee
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Knee Osteoarthritis
Keywords: knee osteoarthritis
Lead sponsor: Laboratoires NEGMA
Sponsor class: INDUSTRY
First posted: 2009-11-09
Enrollment: 210
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective of this study, comparing ART 44 to ART 50, will be the evaluation of digestive tolerability (and in particular of diarrhoea).


Eligibility criteria: Inclusion Criteria:

* Female or Male, aged 40 to 80 years, outpatient;
* Presenting with internal femorotibial osteoarthritis:

  * Symptomatic for more than 6 months;
  * Meeting ACR clinical and radiological criteria;
  * Overall mean VAS score of knee pain in last 24 hours \> 40 mm (with no NSAIDs for over 72 hours and no analgesics for over 24 hours);
  * Pain present for at least one day out of 2 in the month preceding enrolment;
  * Radiological stage II to III (Kellgren and Lawrence) (image less than 12 months old).

Exclusion Criteria:

* Associated predominant symptomatic femoropatellar osteoarthritis;
* Chondromatosis or villonodular synovitis of the knee;
* Paget's Disease.

Primary outcomes:
measure: To demonstrate the better digestive tolerability of ART44 versus ART 50 over a 1-month period, based on a clinically predetermined difference
timeFrame: Day 8, Day 0, Week 2, Week 4 and Week 12
Secondary outcomes:
measure: To compare the overall safety and efficacy of the two products
timeFrame: Day 8, Day 0, Week 2, Week 4 and Week 12
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06564571: Artificial Intelligence in Endoscopic Ultrasound
Official title: Artificial Intelligence in Endoscopic Ultrasound
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pancreatic Cancer
Pancreas Disease
Pancreatic Cyst
Keywords: pancreatic disease
pancreatic cancer
pancreatic cyst
artificial intelligence
Lead sponsor: Orlando Health, Inc.
Sponsor class: OTHER
First posted: 2024-08-21
Enrollment: 310
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any patient 18 years or over undergoing endoscopic ultrasound examination

Brief summary: The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures.

Detailed description: Endoscopic Ultrasound (EUS) is an equipment where an ultrasound transducer is attached to the tip of the endoscope. When advanced to the stomach the organs outside such as the pancreas and liver can be visualized in great detail. This enables diagnosis of conditions such as pancreatic cancer. However, an endoscopist must undergo training to accurately interpret these ultrasound images.

The investigators are in the process of developing an artificial intelligence system that could potentially interpret EUS images. The objective of the study is to determine if this artificial intelligence system is capable of detecting abnormalities in the pancreas that are identified by an endoscopist at endoscopic ultrasound procedures. Such correlation if established will lead to possible development of an artificial intelligence platform that can diagnose pancreatic diseases. Such development will potentially minimize human error and decrease learning curve to gain proficiency in EUS.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Any patient undergoing endoscopic ultrasound examination

Exclusion Criteria:

* Age \< 18 years

Primary outcomes:
measure: Rate of detection pancreatic abnormalities by AI
timeFrame: 1 day
Secondary outcomes:
measure: Rate of detection pancreatic solid mass lesions by AI
timeFrame: 1 day
measure: Rate of detection pancreatic cystic lesions by AI
timeFrame: 1 day
Other outcomes:
Locations:
city: Orlando
country: United States
facility: Orlando Health
state: Florida
Study officials:
affiliation: Orlando Health, Digestive Health Institute
name: Shyam Varadarajulu, MD
role: PRINCIPAL_INVESTIGATOR
References: